| NCT ID | NCT07728123 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Westat |
| Condition | HIV Infections |
| Study Type | INTERVENTIONAL |
| Enrollment | 84,000 participants |
| Start Date | 2026-06-16 |
| Primary Completion | 2028-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 84,000 participants in total. It began in 2026-06-16 with a primary completion date of 2028-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Screen2Prevent is a study intended to improve HIV prevention and detection through implementation and evaluation of three different broad-scale HIV screening approaches a) targeted, b) universally offered opt-in, and c) universally offered opt-out in Emergency Departments (EDs) by leveraging digital health to identify and link adolescents seeking care in the ED to HIV Pre-Exposure Prophylaxis (PrEP)/Antiretroviral treatment (ART).
Eligibility Criteria
Inclusion Criteria: * Age 14-24 years, inclusive * Present to the participating ED, regardless of chief complaint during the study period Exclusion Criteria: * None
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07728123 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 24 Years, studying HIV Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07728123 currently recruiting?
Yes, NCT07728123 is actively recruiting participants. Contact the research team at erinricketts@westat.com for enrollment information.
Where is the NCT07728123 trial being conducted?
This trial is being conducted at Tampa, United States, Atlanta, United States, Baltimore, United States, Memphis, United States and 1 additional location.
Who is sponsoring the NCT07728123 clinical trial?
NCT07728123 is sponsored by Westat. The trial plans to enroll 84,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.